Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# InSphero

## Sitemaps
- [XML Sitemap](https://insphero.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [How Gri3D® Technology and Automated Imaging at Single-Organoid Resolution Deliver Reproducible IC₅₀ Values Across Screening Campaigns](https://insphero.com/gri3d-enables-reproducible-values-in-organoid-screens/): Our CSO, Madhu Nag, writes about how Gri3D® technology and automated imaging at single-organoid resolution enable reproducible IC₅₀ values across screening campaigns, supporting more consistent and scalable organoid-based drug testing.
- [Co-Creating Confidence: Reflections on NAMs from the 16th Global Summit on Regulatory Science](https://insphero.com/nams-reflections-gsrs26-beijing/): InSphero CSO Madhu Nag reflects on the evolving role of New Approach Methodologies (NAMs) in regulatory science following the 16th Global Summit on Regulatory Science in Beijing. Drawing on discussions around validation, standardization, context of use, and reproducibility, the blog explores why regulatory confidence in NAMs must be built collaboratively and how co-creating the evidence base with regulators could help move these models toward broader regulatory use.
- [One Liver Platform, Multiple Questions: From Safety to Translation and Efficacy](https://insphero.com/one-liver-platform-for-safety-translation-efficacy/): The liver plays a central role throughout drug discovery, nonclinical development, and clinical translation. Its importance extends far beyond toxicity. As a major site of drug metabolism and bioactivation, the liver can contribute to influence drug efficacy and safety through metabolism-dependent effects, contribute to species-specific responses, and shape the exposure of other organs to parent compounds and their metabolites.
- [InSphero Appoints Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer](https://insphero.com/insphero-appoints-olivier-frey-coo-cto/): InSphero has appointed Dr. Olivier Frey as Chief Operating Officer and Chief Technology Officer, expanding his leadership role as the company continues to grow and scale. With nearly a decade at InSphero and deep expertise across microfluidics, BioMEMS, 3D in vitro models, and organ-on-chip technologies, Olivier will bring technology and operations into closer alignment. In his new role, he will help advance operational efficiency, digitalization, automation, and technology development across the organization.
- [Human-Relevant, Assay-Ready 3D In Vitro Models for More Predictive Drug Discovery Applications](https://insphero.com/human-relevant-assay-ready-3d-models-drug-discovery/): Human-relevant 3D in vitro models can provide valuable insights into drug safety, efficacy, and disease biology. Yet, establishing these physiologically relevant models internally often requires considerable time, specialist expertise, and laboratory resources.
- [Opinion Letter on In Vitro to In Vivo Extrapolation Applied to Drug Safety Assessment](https://insphero.com/opinion-piece-bruno-filippi-ivive/): The notion of translational toxicology, when applied to drug safety assessment, centres on a deceptively simple question: how can findings obtained outside the human body illuminate the risks faced within it?
- [InSphero Accelerates Global Growth and US Expansion with Acquisition of PhenoVista Biosciences](https://insphero.com/insphero-us-expansion-with-phenovista/): InSphero has acquired California-based PhenoVista Biosciences to expand its US presence and strengthen advanced imaging and phenotypic analysis capabilities for predictive drug discovery and safety testing.
- [Two Teams, One Goal: How the 3D InSight™ DIGIT Platform came to life](https://insphero.com/digit-platform-insphero-doppl-integration-story/): When InSphero acquired DOPPL in January 2026, the goal was not only to expand the portfolio. It was also to bring together complementary expertise and explore what more could be built together.
- [Building the Future of Safety Pharmacology – Our Vision for comprehensive, human relevant drug testing](https://insphero.com/advancing-safety-pharmacology-with-human-relevant-testing/): At InSphero, we have set out to solve a fundamental problem in drug development: the disconnect between preclinical safety testing and human clinical outcomes. Today, as we look at the evolution of our platform, from our gold-standard 3D InSight™ DILI service to the recent launch of our gastrointestinal toxicity screening platform ,we see not just a collection of products, but an integrated strategy coming to life.
- [InSphero Launches 3D InSight™ DIGIT Platform for Early Gastrointestinal Toxicity Assessment ](https://insphero.com/insphero-launches-3d-insight-gi-toxicity-screening-platform/): InSphero has launched the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput solution designed to identify gastrointestinal safety liabilities earlier in drug discovery. Combining patient-derived human intestinal organoids, scalable Gri3D® technology, and automated phenotypic imaging, the platform delivers quantitative, decision-ready insights while enabling more consistent and streamlined GI safety assessment.
- [InSphero and PharmaNest Form a Partnership to Advance Translational Fibrosis Research ](https://insphero.com/insphero-and-pharmanest-partner-for-fibrosis-research/): InSphero has entered a strategic partnership with PharmaNest Inc to advance the translational assessment of fibrosis in human-relevant 3D in vitro models. By combining advanced 3D liver spheroids with high-resolution, AI-enabled digital pathology, the collaboration aims to enable quantitative, phenotype-resolved analysis of fibrotic remodeling and improve the prediction of therapeutic efficacy in complex fibrotic diseases.
- [Industry Leaders Announce World’s First Microphysiological Systems Industry Association (IAMPS) ](https://insphero.com/iamps-insphero-joins-as-a-founding-member/): European microphysiological systems (MPS) industry leaders are announcing today the creation of the Industry Alliance for Microphysiological Systems (IAMPS), the world's first industry association dedicated to represent MPS providers.
- [The NIH Standardized Organoid Modeling (SOM) Institute: Standardization, Regulatory Readiness, and the Next Phase of Human-Relevant Biology ](https://insphero.com/nih-som-standardizing-organoids/): Over the past decade, organoids and other complex human in vitro models have moved from conceptual promise to practical utility across biomedical research. Their ability to recapitulate aspects of human tissue architecture, cellular heterogeneity, and functional response has fundamentally reshaped how disease mechanisms and therapeutic responses can be studied. Yet, despite this progress, the field has faced a persistent bottleneck: insufficient standardization to support reproducibility, scalability, which in turn leads to a lack in regulatory confidence.
- [Redefining Drug Development: How FDA’s Draft Guidance Refines the Regulatory Framework for Non-Human Primate Use](https://insphero.com/human-relevant-safety-science/): The recent draft guidance from the U.S. Food and Drug Administration outlining pathways to reduce non-human primate (NHP) use in monoclonal antibody development marks an important moment for our industry. It reflects what many of us working at the intersection of translational science, safety pharmacology, and regulatory science have long recognized: that advances in human-relevant in vitro models, when rigorously validated and appropriately contextualized, can now meaningfully inform critical development decisions, including when and how NHP studies are conducted.
- [InSphero Expands 3D Cell Model Leadership with Acquisition of DOPPL SA and Sun Bioscience Gri3D® Technology](https://insphero.com/insphero-acquires-doppl-3d-cell-models/): InSphero AG has signed a definitive agreement to acquire DOPPL SA, a Lausanne-based innovator in organoid technologies, including the Sun Bioscience Gri3D® platform. The deal strengthens InSphero’s position as the most comprehensive provider of advanced 3D in vitro models for drug discovery and safety testing.
- [The Human-Centric Mandate: Why NIH and FDA’s Coordinated Push Makes Standardized 3D Models the New Default ](https://insphero.com/human-centric-drug-testing/): The center of gravity in drug development is shifting from animal-first to human-relevant by design. The landscape of preclinical therapeutic development is undergoing a fundamental transformation, driven by an unprecedented, coordinated regulatory and financial push from the United States government. The convergence of recent legislation, strategic regulatory roadmaps, and historic federal funding signals a non-negotiable shift toward human-centric testing and the imminent end of the era of mandatory animal experimentation.
- [Physicians Committee for Responsible Medicine and InSphero Announce Winners of the HUMAIN Award](https://insphero.com/humain-award-2025/): The Physicians Committee and InSphero Launch Award Program to Accelerate Adoption of Human In Vitro Models.
- [The Nobel Prize in Physiology or Medicine 2025: A Celebration of Immune Balance and a Reminder of Why We Build Immune-Competent 3D Models](https://insphero.com/nobel2025-celebrating-discoveries-in-immune-tolerance/): The 2025 Nobel Prize in Physiology or Medicine celebrates the discovery of regulatory T cells (Tregs) and their central role in maintaining immune tolerance, a breakthrough that reshaped modern immunology. At InSphero, this milestone reinforces our mission to integrate immune context into 3D in vitro models. By developing immune-competent systems that capture the balance between activation and suppression, we aim to better reflect human biology in disease research, oncology, and safety testing.
- [InSphero Appoints Werner Lanthaler to Its Board of Directors](https://insphero.com/insphero-appoints-werner-lanthaler-to-its-board-of-directors/): InSphero appoints former Evotec CEO Dr. Werner Lanthaler to its Board of Directors, strengthening its mission to scale reliable 3D in vitro drug testing solutions.
- [Brenus Pharma and InSphero have developed 3D tumor spheroids mimicking in vivo human colorectal cancer conditions and confirming STC-1010’s efficacy](https://insphero.com/brenus-pharma-and-insphero-collaboration/): InSphero announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems.
- [InSphero and Hesperos Announce Strategic Collaboration to Offer End-to-End Solutions in Drug Discovery and Toxicology](https://insphero.com/insphero-hesperos-partnership-mps/): InSphero announced a new collaborative partnership with Hesperos, uniting two leading innovators in the field of advanced in vitro and microphysiological (MPS) systems.
- [InSphero Expands 3D Microtissue Portfolio Through Strategic Agreement with Tessara Therapeutics](https://insphero.com/insphero-tessara-therapeutics-agreement/): InSphero has entered into a distribution agreement with Tessara Therapeutics, an Australian biotech company known for its advanced neuronal microtissue technology. This agreement further strengthens our portfolio of physiologically relevant 3D models and enables us to offer best-in-class neuronal assays to our global customer base.
- [New FDA Roadmap charts a path to reducing animal testing: Progress, promise, and what’s still missing](https://insphero.com/new-fda-roadmap-charts-a-path-to-reducing-animal-testing-progress-promise-and-whats-still-missing/): The FDA’s new roadmap to phase out animal use in preclinical safety testing marks a transformative step toward human-relevant science. By endorsing New Approach Methodologies (NAMs) such as spheroids, organoids, organ-on-chip platforms, and AI-based modeling, the roadmap paves the way for more predictive and ethical drug development. In this post, we highlight what makes this milestone worth celebrating and where stronger focus and collaboration are still needed to turn vision into practice.
- [Diversity in Preclinical Research is Science not Politics: A Key to Safer and More Effective Drug Development](https://insphero.com/diversity-in-preclinical-research/): In recent years, “diversity” has often been discussed in societal and political contexts, sometimes creating misconceptions about its role in science and technology. However, within the field of preclinical drug development, patient diversity is not a political buzzword - it is a scientific imperative.
- [InSphero CSO Dr. Madhu Nag Appointed to SLAS Board of Directors](https://insphero.com/insphero-cso-madhu-nag-slas-board-of-directors/): InSphero is proud to announce that Chief Scientific Officer, Dr. Madhu Nag, has been appointed as a member of the Society for Laboratory Automation and Screening (SLAS) Board of Directors, serving a three-year term starting January 1, 2025. Dr. Nag will also take on the role of Board Secretary.

## Pages
- [Code of Conduct](https://insphero.com/code-of-conduct/): This Code of Conduct describes the values of InSphero and the standards of behavior InSphero expects in its dealings with employees, customers, suppliers, contractors, partners, investors, public authorities, the scientific community, society and the environment.
- [Spheroid & Organoid Technologies](https://insphero.com/technology/spheroid-and-organoid-technologies/): Access both spheroid and organoid technologies within one portfolio, with expert guidance to select the model that best fits your biological question, workflow, and application.
- [DOPPL is now part of InSphero](https://insphero.com/doppl/): DOPPL is part of InSphero, bringing together complementary technologies, scientific expertise, and customer support under one unified organization.
- [3D InSight™ Neural  Microtissues – Production Schedule](https://insphero.com/3d-insight-neural-microtissues-product-schedule/): The table below lists the upcoming production schedule for 3D InSight™ Neural Microtissues. The dates apply to all model configurations. 
- [High Content Imaging (HCI)](https://insphero.com/technology/high-content-imaging-hci/): High-content imaging (HCI) in spheroids is a powerful, histology-like approach that enables detailed analysis of proteins, cells, and tissue architecture within physiologically relevant 3D microtissues. When applied to InSphero’s 3D InSight™ Microtissue Models, HCI captures complex biological responses that closely mirror the in vivo tissue environment. 
- [3D InSight ™ Drug-Induced Gastrointestinal Toxicity Assessment Schedule](https://insphero.com/3d-insight-digit-service-schedule/): Accelerate confident early decision-making with our standardized gastrointestinal cytotoxicity and organoid swelling assay for fast, reliable, and predictive assessment of drug-induced gastrointestinal toxicity (DIGIT) early in your drug discovery pipeline.
- [Ready-to-use Spheroids & 3D cell culture kits](https://insphero.com/ready-to-use-spheroids/): Our Assay-Ready 3D InSight™ Liver, Neural and Islet Microtissues are ready-to-use spheroids, providing immediate access to uniform, QC-qualified pre-aggregated spheroids (one per well) delivered in our Akura™ 96 Spheroid Microplate.
- [Gri3D® Hydrogel Microcavity Technology](https://insphero.com/technology/gri3d-hydrogel-microcavity-technology/): Gri3D® Technology enables the precise and reproducible formation of uniform organoids within ready-to-use hydrogel microplates, bringing true 3D biology to everyday research workflows.
- [3D InSight™ DILI Service Schedule](https://insphero.com/3d-insight-dili-service-schedule/): Streamline your decision-making with our standardized, high-throughput cytotoxicity DILI assay, available with human-derived and species-specific liver models. We offer regular 3D in vitro human and animal DILI testing, evaluating 7 concentrations of your compound in 4 biological replicates over 7, 14 and up to 28 days.
- [RealBrain® Technology](https://insphero.com/technology/realbrain-technology/): To address this challenge, we have joined forces with Tessara Therapeutics, the innovator behind RealBrain® technology.
- [Blog](https://insphero.com/blog/): InSphero scientists share practical insights on 3D cell culture, organ-on-chip, DILI/MASH modeling, and islet biology: methods, case studies, and tips for reproducible results.
- [RNA Sequencing in Spheroids](https://insphero.com/technology/rna-sequencing-in-spheroids/): RNA sequencing in spheroids is a cutting-edge technique used to study gene expression in three-dimensional cellular structures that closely mimic the in vivo environment of tissues. Unlike traditional 2D cultures, 3D spheroids provide a more physiologically relevant context, capturing cell-cell and cell-matrix interactions.
- [Akura™ Organ-on-Chip Technology](https://insphero.com/technology/akura-organ-on-chip-technology/): Akura™ Organ-on-Chip technology is built on pre-formed spheroid and organoid tissue models and is compatible with InSphero’s complete portfolio of 3D InSight™ Human Microtissues. The approach provides experimental continuity between single- and multi-organ testing applications, enabling seamless integration and a step-by-step increase in biological complexity.
- [Akura License Policy](https://insphero.com/akura-license/): This License Agreement (the „License Agreement“) is a legal agreement between the end user („End User“) and InSphero AG or its subsidiaries („InSphero“) to use the Akura™ 96 Spheroid Microplate, Akura™ 384 Spheroid Microplate, Akura™ 384 ImagePro and Akura™ PLUS Hanging Drop System  and Gri3D® Hydrogel Microcavity Plates („Plates“) covered by patents owned or controlled by InSphero which are provided to you.
- [Akura™ Microplate Technology](https://insphero.com/technology/akura-microplate-technology/): The unique features of the microplate technology enable scientists to perform all steps of 3D biological assays: from spheroid formation, long-term experimental protocols, to complex multi-parametric analysis in a single plate. Simple and robust handling is guaranteed for manual pipetting steps as well as when implemented in high-throughput screens. 
- [Medical Disclaimer](https://insphero.com/medical-disclaimer/): Medical Disclaimer: You understand that any information and content, such as text, graphics, and images, found within our Website is for general educational, entertainment, and informational purposes only. You understand that such information is not intended nor otherwise implied to be medical advice or a substitute for medical advice, diagnosis, or treatment.
- [Terms & Conditions](https://insphero.com/terms-and-conditions/): These general terms and conditions of sale of Products and Services (GTCS) shall apply to all Agreements concluded between InSphero and the Customer (each as defined below); (referred to herein each, as a Party, and together as the Parties) and override any conflicting or additional terms and conditions contained in any purchase order or similar documents provided by the Customer to InSphero concerning the purchase or supply of Products or Services. Omission by InSphero to explicitly object or reject terms and conditions provided by the Customer will in no event be construed as an acceptance of any of these terms and conditions of the Customer by InSphero.
- [Privacy Policy](https://insphero.com/privacy-policy/): Privacy Policy – Effective Date: January 1, 2023
- [Careers](https://insphero.com/careers/): At InSphero, we are committed to nourishing our employees' careers and paving the way toward a patient-centered discovery of life-saving drugs for patients worldwide, leveraging the power of 3D Cell Culture technology.
- [3D Cell Culture Tools](https://insphero.com/3d-cell-culture-tools/): For more than a decade, InSphero has developed and optimized technologies for robust and reproducible production, cultivation and assaying of 3D spheroids and organoids. In countless successful collaboration projects with pharmaceutical and biotech partners, our technology has contributed to deep biological insights, better decisions and safer drugs.
- [3D InSight™ Liver Microtissues – Production Schedule](https://insphero.com/production-schedule/): Start your experiment on time with a fast and safe delivery of our3D InSight™ Liver Microtissues from human and preclinical species origin. 
- [Contact Us](https://insphero.com/contact-us/): Talk to Our 3D in vitro Experts and Connect with the InSphero Team
- [Distributors](https://insphero.com/distributors/): By accessing our network of trusted distributors, you can conveniently procure our products, minimize shipping expenses, and save valuable time. Furthermore, our knowledgeable distributors are equipped to provide you with insightful recommendations and guidance, enabling you to make informed purchase decisions.
- [Partners](https://insphero.com/partners/): InSphero partners with leading biotechnological and pharmaceutical companies, academic institutions, and research organizations to advance scientific research and drug development. Through these collaborations, we drive further the development of scalable, reliable, and reproducible 3D cell-based solutions that help researchers yield pragmatic and actionable insights for better and faster decisions.

## Events
- [Microtas 2026](https://insphero.com/events/microtas-2026/): Join us at MicroTAS 2026, taking place October 18-22 in Granada, Spain, for the 30th International Conference on Miniaturized Systems for Chemistry and Life Sciences.
- [ISSX 2026](https://insphero.com/events/issx-2026/): Join us at ELRIG Drug Discovery 2026 in London, where the drug discovery community comes together to explore the latest technologies and approaches shaping preclinical research.
- [Drug Discovery ELRIG 2026](https://insphero.com/events/drug-discovery-elrig-2026/): Join us at ELRIG Drug Discovery 2026 in London, where the drug discovery community comes together to explore the latest technologies and approaches shaping preclinical research.
- [LabTech 2026](https://insphero.com/events/labtech-2026/): Join us at YNOW2026, a Yokogawa Users Conference, in New Orleans, where researchers, innovators, and technology leaders are coming together to explore the future of human-relevant biology, advanced imaging, and translational discovery.
- [BIOSPAIN 2026](https://insphero.com/events/biospain-2026/): Join us at YNOW2026, a Yokogawa Users Conference, in New Orleans, where researchers, innovators, and technology leaders are coming together to explore the future of human-relevant biology, advanced imaging, and translational discovery.
- [Discovery on Target 2026](https://insphero.com/events/discovery-on-target-2026/): Join us at YNOW2026, a Yokogawa Users Conference, in New Orleans, where researchers, innovators, and technology leaders are coming together to explore the future of human-relevant biology, advanced imaging, and translational discovery.
- [ACT 2026](https://insphero.com/events/act-2026/): Join us at YNOW2026, a Yokogawa Users Conference, in New Orleans, where researchers, innovators, and technology leaders are coming together to explore the future of human-relevant biology, advanced imaging, and translational discovery.
- [YNOW 2026](https://insphero.com/events/ynow-2026/): Join us at YNOW2026, a Yokogawa Users Conference, in New Orleans, where researchers, innovators, and technology leaders are coming together to explore the future of human-relevant biology, advanced imaging, and translational discovery.
- [EASD 2026](https://insphero.com/events/easd-2026/): Explore all our activities taking place during EASD 2026, from Monday, September 28th to Friday, October 2nd. See you in Milan!
- [HIRN Investigator Meeting 2026](https://insphero.com/events/hirn-investigator-meeting-2026/): Join us at the MPS World Summit 2026 in Washington, DC, where the global community comes together to advance microphysiological systems and human-relevant models.
- [SPS 2026](https://insphero.com/events/sps-2026/): Explore our activities at SPS 2026, from September 21st to 23rd. See you in Montréal!
- [EUROTOX 2026](https://insphero.com/events/eurotox-2026/): Join us at EUROTOX 2026 in Vienna, Austria, where the global toxicology community will come together to exchange scientific advances, explore emerging approaches, and shape the future of safety assessment.
- [Joint Webinar: ZEISS Lightfield 4D for High-Content Tumor Microtissue Screening: From Reliable and Scalable 3D Models to Quantitative Insights](https://insphero.com/events/webinar-zeiss-lightfield-4d-hc-organoid-screening/): In this webinar, Peter Favreau of ZEISS and Olivier Frey of InSphero examine how standardized 3D cancer models, fast volumetric microscopy, and advanced image analysis can be combined to support more efficient and quantitatively robust tumor microtissue screening.
- [SBI2 Europe 2026](https://insphero.com/events/sbi2-europe-2026/): Don't miss us at SBI2 Europe 2026 in Boston, Cambridge, UK! 
- [JSOT 2026](https://insphero.com/events/jsot-2026/): Under the theme “Evolving Toxicology - Innovation Emerging from the Confluence of Diverse Fields,” JSOT 2026 will bring together experts from toxicology, life sciences, chemistry, environmental science, AI, data science, and regulatory science to discuss how new methods and collaborations are shaping the future of toxicology.
- [EISG 2026](https://insphero.com/events/eisg-2026/): Connect with our team for the European Islet Study Group Conference, a focused meeting dedicated to advancing the understanding of islet biology and its role in diabetes research.
- [NAMs Industry Mixer at BIO Convention 2026](https://insphero.com/events/nams-industry-mixer-at-bio-convention-2026/): The NAMs Industry Mixer is designed as a focused meeting point for the global MPS and NAMs. At a convention where pharma, biotech, regulators, investors, technology providers, and innovators come together, this event offers a dedicated space to meet peers, continue conversations, and build new relationships beyond the busy exhibition floor.
- [MPS World Summit 2026](https://insphero.com/events/mps-world-summit-2026/): Join us at the MPS World Summit 2026 in Washington, DC, where the global community comes together to advance microphysiological systems and human-relevant models.
- [From Fibrosis Mechanisms to Medicine: 3D Spheroid Models of MASH for Translational Discovery](https://insphero.com/events/webinar-mash-fibrosis-3d-spheroid-models/): In this webinar, on Tuesday, May 12th, 2026, at 11 am EDT, InSphero, together with PharmaNest and Icahn School of Medicine at Mount Sinai, New York,  explored how emerging therapeutic strategies and enabling technologies are shaping the future of MASH treatment, focusing on the continued importance of anti-fibrotic approaches, advanced 3D human in vitro models, and AI-driven digital pathology.
- [AACR 2026](https://insphero.com/events/aacr-2026/): AACR 2026 takes place from April 17-22, and we look forward to connecting with you in San Diego!
- [Keystone Symposia 2026](https://insphero.com/events/keystone-symposia-2026/): Keystone Symposia 2026 takes place March 16th to 19th in Breckenridge, Colorado, bringing the diabetes research community together for “Islet Biology and Diabetes: Beta Cell Compensation, Failure and Recovery.”
- [PBSS 2026](https://insphero.com/events/pbss-2026/): Meet us in Foster City, California, for a dedicated workshop on:
- [SOT 2026](https://insphero.com/events/sot-2026/): The Society of Toxicology (SOT 2026) annual meeting will be hosted in San Diego, California, bringing together toxicology experts and academics from around the world! 
- [Japan MPS Initiative 2026](https://insphero.com/events/japan-mps-initiative-2026/): The Japan MPS Initiative 2026 brings together leading experts in microphysiological systems and organ-on-chip technologies to discuss the latest scientific advances shaping drug discovery, toxicology, and regulatory science.
- [World Organoid Research Day 2026 (WORD+)](https://insphero.com/events/world-organoid-research-day-2026/): WORD+ 2026 is the 4th annual gathering for innovators advancing organoid, organ-on-a-chip, and New Approach Methodologies,  bringing together researchers and industry leaders to share insights on 3D in vitro systems and scalable workflows.

## Products
- [Assay-Ready 3D InSight™ Species-Specific Liver Microtissues](https://insphero.com/product/species-specific-liver-microtissues/): 3D InSight™ Species-Specific Liver Microtissues enable direct comparison of hepatotoxicity across human and preclinical species, helping determine whether animal safety signals are relevant to humans and strengthening translational confidence.
- [Gri3D® Hydrogel Microcavity Plates](https://insphero.com/product/gri3d-microplate/): Gri3D® Hydrogel Microcavity Plates combine precisely defined arrays of PEG hydrogel microcavities with a standard 96-well plate format to provide a controlled environment for 3D cell culture. The unique design enables cells to self-organize into uniform spheroids and organoids, supporting reproducible tissue formation across a broad range of biological models. As a ready-to-use platform, Gri3D® integrates seamlessly into both manual and automated workflows.
- [Assay-Ready 3D InSight™ Human Liver Microtissues](https://insphero.com/solutions/liver-safety/3d-insight-human-liver-microtissues/): Streamline your research with standardized, ready-to-use, primary cell-based 3D liver models in high-density culture format.
- [Akura™ Immune Flow Organ-on-Chip Platform](https://insphero.com/3d-cell-culture-tools/akura-immune-flow-organ-on-chip-platform/): Bring the Akura™ Immune Flow Organ-on-Chip System into your lab by acquiring our starter kit offering. It’s everything you need to immediately begin investigating complex biological questions in your research:
- [Akura™ Flow Organ-on-Chip Platform](https://insphero.com/3d-cell-culture-tools/akura-flow-organ-on-chip/):  The Akura™ Flow Organ-on-Chip Platform is a multi-organ system engineered to be compatible with spheroids and organoids, including our complete portfolio of 3D InSight™ Microtissues.
- [3D InSight™ Human Islet Microtissues](https://insphero.com/solutions/islet-biology/3d-insight-human-islet-microtissues/): 3D InSight™ Islet Microtissues, produced by reaggregation of dispersed human islet cells, are a standardized alternative to primary human pancreatic islets. They mimic the complex architecture and function of human pancreatic islets while significantly expanding their ex vivo life-span, functional responses and automation compatibility.
- [Akura™ Twin Organ-on-Chip Platform](https://insphero.com/3d-cell-culture-tools/akura-twin-organ-on-chip-platform/): The Akura™ Twin Organ-on-Chip Platform is designed for organ-organ cross-talk in the presence of immune cells with robust handling as well as reliable culturing and analysis.
- [InSphero Incubox™](https://insphero.com/3d-cell-culture-tools/insphero-incubox/): The InSphero Incubox™ is a specially engineered container that creates a high-humidity microclimate inside conventional cell culture incubators and protects your sensitive plates from large humidity drops and fluctuations – the major cause for evaporation effects.
- [Akura™ PLUS Hanging Drop System](https://insphero.com/3d-cell-culture-tools/akura-plus-hanging-drop-system/): The world-famous and unique Akura™ PLUS Hanging Drop System in a 96-well format with automation-compatible top-loading.
- [Akura™ Tilting Stand](https://insphero.com/3d-cell-culture-tools/akura-tilting-stand/): The Akura™ Tilting Stand is a convenient multi-purpose tool for different handling steps with our Akura™ Plate family. It keeps plates at an angle of 30 degrees during cell aggregation improving spheroid/organoid uniformity. It is also used for medium loading and exchange in the Akura™ Flow 384 Plate.
- [Akura™ 96 Spheroid Microplate](https://insphero.com/3d-cell-culture-tools/akura-96-spheroid-microplate/): The Akura™ 96 Spheroid Microplate is the super convenient culturing plate for your daily spheroid/organoid culturing in every lab environment, from manual to automated handling. The plate is designed for lossless spheroid/organoid formation and handling as well as reliable cell culturing and analysis.
- [Akura™ 3D SureKit](https://insphero.com/solutions/liver-safety/akura-3d-surekit/): The Akura™ 3D SureKit provides a validated all-in-one solution to generate and culture organotypic 3D spheroids from primary human hepatocytes.
- [Akura™ 384 Spheroid Microplate](https://insphero.com/3d-cell-culture-tools/akura-384-spheroid-microplate/): The Akura™ 384 Spheroid Microplate is our ultimate spheroid screening plate unifying robust liquid and spheroid handling with automated high-throughput screening applications. The flat bottom and black walls of the InSphero 384-well plate facilitate fluorescent imaging, while the special well design allows medium exchange, dosing, and endpoint determination in the same plate saving time and resources.

## Resources
- [A DPP6-Targeted PET Tracer for Non-Invasive Imaging of Transplanted Human Islets](https://insphero.com/resource/dpp6-pet-imaging-transplanted-human-islets/): Amina Khalil, Arturo Roca-Rivada, Svitlana Vasylovska, Lorenzo J. I. Balestri, Irina Velikyan, Sayro Jawurek, Alexandra C. Title, Burcak Yesildag, Luke R. Odel, Joey Lau, Decio L. Eizirik & Olof Eriksson
- [3D InSight™ Liver Microtissues as Promising Pre-clinical Safety Assessment In Vitro Tools: Mechanistic Investigation of Aflatoxin B1 Toxicity in Dog, Rat and Human](https://insphero.com/3d-liver-microtissues-aflatoxin-b1-safety/)
- [An integrative in silico toolbox for derisking drug-induced liver injury (DILI) liabilities](https://insphero.com/in-silico-toolbox-drug-induced-liver-injury/)
- [Polyadenylation of insulin mRNA by Tent5a regulates pancreatic beta cells](https://insphero.com/resource/tent5a-polyadenylates-insulin-mrna-in-pancreatic-beta-cells/): Pamuditha N. Silva, Johanna E. Mayrhofer, Pavlo Potalitsyn, Geraldine O. Trüllinger, Svenja Godbersen, Nic Amstutz, Sebastian M. Siegner, Ben Kodiyan, Alexandra C. Title, Burcak Yesildag, Jacob E. Corn, Marc W. Schmid & Markus Stoffel 
- [Scalable Pharmacological Profiling of 3D InSight™ Human Neural Microtissues Using High-Density MEAs](https://insphero.com/resource/3d-human-neural-microtissues-for-pharmacological-profiling/): Discover how InSphero’s 3D InSight™ Human Neural Microtissues and MaxWell Biosystems’ MaxTwo Multiwell HD-MEA System combine human-relevant 3D neural biology with high-content functional electrophysiology. This application note demonstrates scalable, label-free profiling of spontaneous and compound-modulated neuronal network activity, capturing distinct responses to excitatory and inhibitory reference compounds. Advanced network and burst-shape analyses further reveal subtle, mechanism-dependent differences in network dynamics, providing deeper functional insight for compound screening, safety assessment, and neuropharmacology.
- [3D InSight™ Human Neural Microtissues: Ready-to-use 3D cortical neural spheroids for scalable CNS safety and neurotoxicity screening   ](https://insphero.com/resource/3d-insight-human-neural-microtissues-poster/)
- [Toward Patient-Relevant DILI Testing: Integrating Intrinsic Liver Vulnerability with Systemic Metabolic Cues](https://insphero.com/resource/dili-testing-with-liver-vulnerability-and-metabolic-cues/)
- [Enabling Early Safety Assessment with Low-Input RNA-Seq in Liver Microtissues Across Species and Compound Analogs](https://insphero.com/resource/low-input-rna-seq-for-liver-safety-across-species/)
- [Excessive EFHD1-dependent ER-mitochondrial contacts drive a maladaptive antiviral response in metabolic liver disease](https://insphero.com/resource/efhd1-liver-injury-metabolic-liver-disease/): David R. Eberhardt, Emma C. Rekate, Yasmin B. Masini, Hannah E. Duron, David Mollinedo, Adrian M. Velarde, Devorah Stucki, Tara R. Price, Sandra H.J. Lee, EnriqueBalderas, Neeraj K. Rai, Ashley R. Bratt, Anthony M. Balynas, Chris J. Stubben, Ryan Bia, Sudipa Maity, Nicolas Hartel, Xue Yin, Andrea Corbin, Anshu Kumari, Dung M.Nguyen, Daisuke Shimura, Vu D. Nguyen, Vishaka Vinod, Kamrul H. Chowdhury, Francisco Verdeguer, Joel Zvick, Patrice N. Mimche, Sihem Boudina, Stavros G. Drakos,Ademuyiwa S. Aromolaran, Sarah Franklin, Vivek Garg, Robin M. Shaw, William L. Holland, Scott A. Summers, Marcus G. Pezzolesi, Jared Rutter, Kimberley J. Evason,Dipayan Chaudhuri
- [ZEISS Lightfield 4D for High-Content Tumor Microtissue Screening: From Reliable and Scalable 3D Models to Quantitative Insights](https://insphero.com/resource/lightfield-4d-tumor-microtissue-screening/): In this webinar, Peter Favreau of ZEISS and Olivier Frey of InSphero examine how standardized 3D cancer models, fast volumetric microscopy, and advanced image analysis can be combined to support more efficient and quantitatively robust tumor microtissue screening.
- [Brochure 3D InSight™ Human Neural Microtissues](https://insphero.com/resource/3d-insight-human-neural-mts/): Learn how 3D InSight™ Human Neural Microtissues can support earlier CNS safety decisions.
- [A scalable microarrayed organoid platform for precision modeling of intestinal epithelial damage and recovery](https://insphero.com/resource/scalable-organoid-model-of-intestinal-damage-and-recovery/): Marine Meyer, Aline Roch, Juliane Dervaux, Laurent Ferrier, Evarist Planet, Julien Duc, Camilla Ceroni, Mariana Costa, Brice Chambrin, Jens Stolte, Sylviane Métairon, Abhilash Kannan, Sylke Hoehnel-Ka, Marine R.-C. Kraus, Patrick Descombes, Nathalie Brandenberg, Mario Noti, & Omid Mashinchian
- [Safety and Efficacy of HexaBody-DR5/DR5 in MalignantSolid Tumors: Phase 1/2a Results and Translational InsightsInto Observed Hepatotoxicity](https://insphero.com/resource/hexabody-dr5-in-solid-tumors-safety-and-hepatotoxicity/): Marije B. Overdijk, Kristin Strumane, Ruth Plummer, Patricia LoRusso, Jordi Rodon Ahnert, Udai Banerji, Elena Garralda, Emiliano Calvo, Han Si, Naomi Hoevenaars, Jens Thing Mortensen, Sieto Bosgra, Anders Malmberg, Merete Ellekilde-Pedersen, Teresa Ramirez-Andersen, Panagiota Diamantopoulou Reiter, Elena Favaro, Ulf Forssmann, Esther C. W. Breij & Maria Jure-Kunkel
- [Complex in vitro model developers’ perspective on advanced hepatic in vitro culture methods for predictive drug safety](https://insphero.com/resource/advanced-hepatic-in-vitro-models-perspective/)
- [Studying Fibrosis using 3D InSight Human MASH Microtissues Leveraging ZEISS Lattice Lightsheet 7 for 3D High-Content Analysis](https://insphero.com/resource/zeiss-ins-3d-mash-microtissues-for-fibrosis/)
- [Scalable Whole-Plate Calcium Imaging of Human iPSC-Derived Neural Spheroids for Drug Screening and Neurotoxicity Assessment](https://insphero.com/resource/ipsc-neural-spheroid-calcium-imaging-for-drug-screening/)
- [Non-Destructive Multiplexed Imaging of 3D Liver Microtissues for Multi-Modal DILI Assessment](https://insphero.com/resource/imaging-of-3d-microtissues-for-multi-modal-dili-assessment/)
- [High-throughput single organoid swelling assay for personalized evaluation of CFTR modulators in patient-derived rectal organoids](https://insphero.com/resource/high-throughput-cftr-testing-rectal-organoids/)
- [Influence of 3-dimensional architecture and coculture on in vitro CYP enzyme metabolism and induction: Benchmarking human hepatic spheroids for studies in drug development](https://insphero.com/resource/3d-hepatic-spheroids-cyp-metabolism-induction/): Ann-Kathrin Lenich, Sanja Alsdorf & Stephanie Ruez
- [A Long‐Term Human Liver Spheroid Model for Assessing Silencing and Durability of GalNAc‐Conjugated siRNAs](https://insphero.com/resource/long-term-human-liver-spheroid-model-galnac-sirnas/): Gijs-Jan Scholten, Clara Grundmann, Asa Nordling, Caroline Coskun, Volker Engerlhardt, Lingheswar Sadhasivam, Tomaz Einfalt, Magnus Ingelman-Sundberg & Sander van Riet
- [The dual integrin inhibitor Bexotegrast, indicated for idiopathic pulmonary fibrosis, shows an anti-fibrotic phenotype in human MASH liver spheroids](https://insphero.com/resource/bexotegrast-reduces-fibrosis-human-mash-spheroids/)
- [Evaluation of drug-induced liver injury of Trovafloxacin and Chlorpromazine in human InSight™ 3D MASLD spheroid model](https://insphero.com/resource/evaluation-of-drug-induced-liver-injury-of-trovafloxacin-and-chlorpromazine-in-human-insight-3d-masld-spheroid-model/)
- [Utilizing Cross-species In Vitro Models to Proactively Flag DILI Mechanisms Missed by Traditional Preclinical Testing](https://insphero.com/resource/utilizing-cross-species-in-vitro-models/): This white paper explores how advanced cross-species 3D liver microtissues can improve mechanistic DILI prediction and support proactive preclinical de-risking strategies. Using the case of amcenestrant, a selective estrogen receptor degrader (SERD) associated with cholestatic liver injury in dogs, the study demonstrates how species-specific 3D InSight™ Liver Microtissues successfully identified the underlying mechanism of toxicity that conventional models failed to detect.
- [From Fibrosis Mechanisms to Medicine: 3D Spheroid Models of MASH for Translational Discovery](https://insphero.com/resource/3d-spheroid-models-of-mash/): Watch this on-demand webinar from InSphero, PharmaNest, and Icahn School of Medicine at Mount Sinai exploring why anti-fibrotic therapies remain critical in the GLP-1 era for MASH.
- [3D InSight™ Drug-Induced Gastrointestinal Toxicity Assessment – The human small intestinal organoid assay for drug testing](https://insphero.com/resource/drug-induced-gi-toxicity-organoids/)

## Services
- [3D InSight™ Predictive Toxicology Service | 3D In Vitro DILI Testing](https://insphero.com/solutions/liver-safety/predictive-tox-dili/): At InSphero, we offer industry-leading in vitro DILI testing that enables early identification of highly toxic compounds through a physiologically relevant liver model compatible with high-throughput screening. Our 3D InSight™ Liver Microtissues support a broad range of therapeutic modalities, including small molecules and antisense oligonucleotides (ASOs).
- [3D InSight™ Human Beta Cell Proliferation Service – Copy](https://insphero.com/service/type-1-diabetes-platform/): Access our peer-reviewed paper on Type 1 Diabetes:
- [3D InSight™ Translational Toxicology Service | 3D In Vitro Liver Safety Services](https://insphero.com/service/translational-toxicology-service/): Support up to 28-day translational toxicology studies with repeated compound applications.
- [3D InSight™ Human Beta Cell Proliferation Service](https://insphero.com/solutions/islet-biology/beta-cell-proliferation/): Isolated donor islets, traditionally used for the study of human β-cell proliferation, suffer from rapidly deteriorating viability and function ex vivo in their intact form, and once dispersed, their β-cells dedifferentiate and hyperproliferate in culture. In contrast, islet microtissues, produced by reaggregation of gently dispersed human islet cells, represent a uniform, functionally robust and long-lived in vitro islet model that preserve native-like endocrine composition and cell-to-cell interactions critical for physiologically relevant proliferative responses. Uniquely, long-term stable functionality and viability of islet microtissues enables in vitro assessment of changes in β-cell and islet mass in addition to proliferation.
- [3D InSight™ Therapeutic Modality Screening](https://insphero.com/solutions/oncology-and-immunology/therapeutic-modality-screening/): Our 3D InSight™ Oncology platform mimics the physiology and the heterogeneity of the tumor microenvironment and patient-specific characteristics, offering a reliable, accurate in vitro model to test your pipeline of innovative cancer therapeutics. Our 3D InSight™ Oncology platform allows you to get robust, reproducible, and physiologically relevant results for any therapeutic candidate in your discovery program with days to weeks turnaround times.
- [3D InSight™ Immuno-Oncology Screening](https://insphero.com/solutions/oncology-and-immunology/immuno-oncology-screening/): In vitro immuno-oncology (IO) therapeutics testing is used to evaluate the efficacy, mechanism of action, and resistance to cancer immunotherapies before they advance into more costly preclinical and clinical development. By co-culturing 3D tumor spheroids with Peripheral Blood Mononuclear Cells (PBMCs) or specific immune cell subpopulations such as T cells, NK cells, or macrophages, it is possible to investigate immune-cell activation, tumor killing, cytokine release, immune-cell infiltration, and IO treatment efficacy within a physiologically relevant solid tumor-like microenvironment. 
- [3D InSight™ | 3D In Vitro MASH Screening for Lead Selection](https://insphero.com/solutions/liver-disease/nash-preventive-screening/): Innovative therapies for MASH (Metabolic Dysfunction-associated Steatohepatitis, renamed from NASH) remain a critical unmet medical need. Our MASH Screening Program is designed to support your MASH drug discovery and developmental pipeline in identifying, prioritizing, and de-risking MASH drug candidates early on, using a robust, human-relevant 3D liver MASH model.
- [MASH CALL for Fast and Reliable Identification and Comparison of Drug Candidates](https://insphero.com/service/mash-call-liver-disease/): Join our MASH CALL Initiative and leverage our pioneering approach for drug discovery with valuable insights about the:
- [3D InSight™ | 3D In Vitro MASLD Model for Liver Discovery](https://insphero.com/solutions/liver-disease/nafld-screening/): Leveraging InSphero's market-leading 3D InSight™ MASH model, our 3D In Vitro MASLD model offers equivalent advantages for fatty liver disease research. Experience a high-quality, scalable, and human-relevant 3D cell culture disease model that generates precise insights and facilitates efficient research throughput. Rely on our expertise in creating primary-cell spheroid models and inducing specific disease phenotypes, enabling us to tailor solutions to your needs - fast and efficient for early-stage decision-making.
- [3D InSight™ Investigative Liver Safety Services | 3D In Vitro Liver Safety Services](https://insphero.com/solutions/liver-safety/investigative-tox/): InSphero’s Investigative Toxicology services offer a comprehensive set of solutions to decipher the mechanism of toxicity of a substance. Profiling and hypothesis generation are supported by state-of-the art ‘omics technology, while a comprehensive portfolio of biomarker analysis and classical toxicology mechanistic assays can test a broad set of toxic reactions. InSphero’s team supports you in identifying potential hepatotoxic substances and understanding their mechanisms of toxicity to guide your risk assessment with confidence within weeks.

## Solutions
- [Spheroid & Organoid Model Development](https://insphero.com/solutions/spheroid-and-organoid-model-development/): InSphero combines deep expertise in spheroid and organoid model development with proprietary technologies designed to improve reproducibility, scalability, and integration into drug discovery workflows.
- [3D InSight™ Human Neural Microtissues](https://insphero.com/solutions/human-neural-microtissues/): Many early CNS safety workflows still rely on 2D neuronal cultures, which fail to capture the spatial organization, cellular interactions, and network behaviour of the human brain, limiting their predictive value. Human neural microtissues are 3D neural spheroids that better replicate the architecture, cell-cell interactions, and functional neuronal network activity of brain tissue than conventional 2D in vitro cultures.
- [3D InSight™ Tumor Penetration Screening](https://insphero.com/solutions/3d-insight-tumor-penetration-screening/): Our established 3D InSight™ Tumor Penetration Screening platform enables scalable, image-based evaluation of biologics antibody penetration and target localization in human 3D tumor models at single-cell resolution. 
- [3D InSight™ I 3D In Vitro Gastrointestinal Toxicology](https://insphero.com/solutions/3d-insight-gastrointestinal-toxicology/): Drug-Induced Gastrointestinal Toxicity (DIGIT) is a major driver of dose-limiting adverse events, imposing significant patient burden and contributing to treatment discontinuation and clinical attrition. Despite its clinical importance, early predictive assessment of gastrointestinal (GI) risk remains limited.
- [Gri3D®](https://insphero.com/solutions/gri3d/): The Gri3D® Hydrogel Microcavity Plates from SUN Bioscience are joining the InSphero Akura™ family. Expanding our portfolio of advanced 3D cell culture solutions.
- [Liver Safety](https://insphero.com/solutions/liver-safety/): Your proven end-to-end 3D in vitro liver safety solution portfolio - from reliable hazard identification to insights into translational and clinical toxicology
- [Islet Biology](https://insphero.com/solutions/islet-biology/): Your complete end-to-end solution portfolio for the study of islet function, β-cell regeneration and β-cell preservation in physiologically relevant disease models
- [Oncology and Immunology](https://insphero.com/solutions/oncology-and-immunology/): Uncover valuable insights into mechanisms of action and the effect of multiple cell types in Oncology and Immunology by using our physiologically relevant and scalable 3D Human tumor models.
- [Liver Disease](https://insphero.com/solutions/liver-disease/): Imagine the complex nature of liver disease biology condensed into a few plates of assay-ready 3D microtissues. InSphero's 3D in vitro liver disease platform provides you with data and insights that exponentially accelerate your research in MASH (NASH) and MASLD (NAFLD) drug discovery.